King's Research Portal

DOI:

[10.1192/bjp.2018.233](https://doi.org/10.1192/bjp.2018.233)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Strawbridge, R., Carter, B., Marwood, L., Bandelow, B., Tsapekos, D., Nikolova, V. L., Taylor, R., Mantingh, T., De Angel, V., Patrick, F., Cleare, A. J., & Young, A. H. (2018). Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. *British Journal of Psychiatry*, 214(1), 42-51.
<https://doi.org/10.1192/bjp.2018.233>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Augmentation therapies for treatment-resistant depression: a systematic review and meta-analysis

Rebecca Strawbridge^{1*}, Ben Carter², Lindsey Marwood¹, Borwin Bandelow³, Dimosthenis Tsapekos¹, Viktoriya L Nikolova¹, Rachael Taylor¹, Tim Mantingh^{1, 4}, Valeria de Angel^{1, 4}, Fiona Patrick¹, Anthony J Cleare^{1,4}, Allan H Young^{1,4}.

¹ Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

² Department of Biostatistics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

³ Department of Psychiatry and Psychotherapy, University Medical Centre, Göttingen, Germany

⁴ South London & Maudsley NHS Foundation Trust, London, UK.

* Corresponding author:

Email address: becci.strawbridge@kcl.ac.uk

Telephone number: +44 207 848 5305

Full postal address: Centre for Affective Disorders, PO74 Institute of Psychiatry, Psychology & Neuroscience, King's College London, 103 Denmark Hill, London, SE5 8AZ

Keywords: treatment-resistant depression; augmentation; psychological therapy; psychopharmacology; systematic review; meta-analysis.

Abstract

Background: Depression is now considered to have the highest disability burden of all conditions. Although treatment-resistant depression (TRD) is a key contributor to that burden, there is little understanding of the best treatment approaches for those who do not respond adequately to antidepressant treatments and specifically the effectiveness of available augmentation approaches.

Aims: We conducted a systematic review and meta-analysis (Prospero registration CRD42018088009) aiming to search and quantify the evidence of psychological and pharmacological augmentation interventions for TRD.

Methods: Trials where patients with TRD were randomised to at least one augmentation treatment were included, where treatment resistance was defined as insufficient response to at least two antidepressant treatments in the current episode. Pre-post analysis assessed treatment effectiveness, providing an effect size (ES) independent of comparator interventions.

Results: Of 28 included trials, only 3 investigated psychological treatments, while 25 examined pharmacological interventions. Assessing treatment classes, pre-post analyses demonstrated N-methyl-D-aspartate targeting drugs to have the highest effect size (ES=1.48, 95%CI 1.25–1.71). Other than aripiprazole (4 studies, ES=1.33, 95%CI 1.23–1.44) and lithium (3 studies, ES=1.00, 95%CI 0.81–1.20), treatments were each investigated in less than three studies. Overall, pharmacological (ES=1.19, 95%CI 1.80–1.30) and psychological (ES=1.43, 95%CI 0.50–2.36) therapies yielded higher effect sizes than pill placebo (ES=0.78, 95%CI 0.66–0.91) and psychological control (ES=0.94, 95%CI 0.36–1.52).

Conclusions: Despite being used widely in clinical practice, the evidence for augmentation treatments in TRD is sparse. Although pre-post meta-analyses are limited by the absence of direct comparison, this work finds promising evidence across treatment modalities.

Declaration of interest

Prof Young has received honoraria for speaking from Astra Zeneca, Lundbeck, Eli Lilly, Sunovion; honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion, Janssen; and research grant support from Janssen, in the last 3 years. Prof Cleare has received honoraria for speaking from Astra Zeneca and Lundbeck, honoraria for consulting with Allergan, Janssen, Livanova, Lundbeck and Sandoz and support for conference attendance from Janssen and research grant support from Lundbeck, in the last 3 years. Dr Bandelow has (recently/soon) to be on the speakers/advisory board for: Hexal, Lilly, Lundbeck, Mundipharma, Pfizer, and Servier. No other conflicts of interest are declared.

Relevance Statement

This manuscript is submitted for the “treatment-resistant mood disorders” Themed Issue.

Despite having substantial burden, treatment-resistant depression (TRD) has received little research attention and clinicians do not have consistent guidelines for treating the illness. We systematically reviewed the evidence of augmentation treatment effectiveness, since most TRD patients are treated with augmenters. In contrast to previous meta-analyses, we focus on the most common clinical TRD definition and provide pre-post effect sizes for psychological and pharmacological therapies. Although the evidence is scant (28 randomised trials), findings demonstrate effectiveness of aripiprazole and lithium, and particular early-stage promise for ketamine, minocycline and intensive CBT.

Introduction

The burden of treatment resistant depression (TRD) is challenging to quantify, TRD having eluded a universal definition¹ but being prevalent and encompassing considerably greater severity, chronicity, recurrence, hospitalisation and comorbidity with both psychiatric and non-psychiatric disorders than non-resistant major depressive disorder (MDD)². Despite this, TRD has been a neglected area of research with numerous reviews calling for more comprehensive evidence. Indeed, many of these reviews have considered patients as treatment resistant if they have failed one previous treatment trial (in contrast with the most popular guidelines¹), in part because this represents the inclusion criteria frequently used in clinical trials. One such example examined pharmacological augmentation treatments which the majority of TRD patients are treated with in practice³. Only when using the less stringent criteria of TRD was there sufficient evidence for a network meta-analysis in 2015³, and the authors reported significant efficacy of quetiapine, aripiprazole, lithium and thyroid hormone compared to placebo. However, this evidence may not apply to patients with more severe TRD. Pre-post analyses have the benefit of not requiring a placebo arm and the ability to compare effectiveness estimates between heterogeneous treatment approaches⁴. Additionally, pre-post effect sizes provide good clinical face validity as an estimate of the magnitude of effects seen with treatment in practice, incorporating both those specific to the individual modality as well as non-specific effects and the passage of time⁴.

Objectives

This review aimed to qualify and quantify the evidence of augmentation treatments for TRD, using the most common clinical definition (i.e. ≥ 2 failed treatments in current episode), and to compare effect sizes (ES) across psychological and pharmacological interventions. To our knowledge, this is the first meta-analysis comparing pre-post treatment effects for all augmentation therapies across the two most popular treatment classes for depression in clinical practice. Specifically, our objectives were to:

1. Determine the efficacy of adjunctive interventions for TRD, through comparisons between treatment category (i.e. pharmacological or psychological), class (e.g. antipsychotics, mood stabilisers) and individual treatments.
2. Provide an indication of the acceptability and tolerability of these treatments.

Methods

Criteria for considering studies for the review

The protocol for this systematic review was published via PROSPERO⁵, where full details of the search are available and reported consistently following the PRISMA reporting guidelines.

Types of included studies

Only randomised controlled trials (RCT) of at least 10 participants, to at least one suitable augmentation treatment were included.

Types of participants

Participants must have been adults with TRD, defined as unremitted depression despite at least two courses of treatment of adequate dose and duration undertaken in the current episode (current best practice guidelines⁶). It has been considered that both within-class (in addition to between-class) switching of antidepressants, and psychological treatments are valid contributors to a TRD definition¹; as such, these were permitted. Due to clear treatment distinctions, studies including patients with psychotic or bipolar depression were excluded.

Types of interventions

Patients must have been taking at least one continuation treatment prior to randomisation to a new (augmentation) intervention. The same eligibility criteria were employed for both continuation and augmentation treatments: permitted pharmacological treatments were any included in the Maudsley Treatment Inventory¹ and psychological treatments from the NICE depression guidelines⁷ or those with multiple meta-analyses supporting

use in depression. Eligible comparator treatments included pill placebo, another pharmacological agent, another psychological intervention, waiting list, active control, or treatment-as-usual (TAU).

Types of outcome measures

Primary outcome: Clinical improvement (ES) between pre- and post-treatment time points, for each eligible treatment/comparator arm. One efficacy measurement was selected, prioritising validated, clinician-rated measures of depression severity (and if not available, a patient-rated depression scale or assessment of global improvement if no depression symptom scale was reported).

Secondary outcomes: A measure of adherence/compliance (e.g. any-cause trial dropout or treatment adherence data) and a measure of tolerability (e.g. adverse event or side effects data) were recorded where available.

Search methods for identification of studies

MEDLINE and ISI Web of Science were searched in addition to citation lists from notable papers, available reviews and included articles. The following medical subject headings or text word terms were used for the electronic database search [all fields]: (depress* OR MDD OR major depress*) AND (resistan* OR refractor* OR non-respon* OR nonrespon* OR un-respon* OR unrespon* OR TRD OR fail* OR inadequate OR difficult OR intractable) AND (augment* OR adjunct* OR add-on OR combin* OR co-administ*) AND (randomi* OR RCT) AND (treatment OR intervention OR trial). No language restriction was made.

Data collection and analyses

Article review and data extraction

All search results were evaluated against inclusion criteria independently by pairs of review authors (RS, LM, RT, TM, VA, DT, VN, FP) with disparities addressed by consensus with additional review authors (AHY, AJC, BC). Following inclusion, data extraction was conducted by authors as above.

Quality assessment

The methodological quality assessment was examined using the Scottish Intercollegiate Guidelines Network (SIGN)⁸ and the Cochrane risk of bias (RoB)⁹ tools. Studies were assessed by two reviewers (rated as RoB high, low or unclear) for nine domains: sequence generation, allocation concealment, blinding of outcome assessors, use of intention-to-treat (ITT) analysis, comparability of randomised groups at baseline, inter-site differences in findings, the potential for selective outcome reporting and presence of for-profit bias (allegiance). Using individual criterion ratings, each study was given an overall RoB rating of low, moderate or high RoB (see Supplementary Table 1).

Measures of treatment effect

Continuous data describing treatment effectiveness were extracted (e.g. pre- and post-severity scores, or longitudinal change in severity scores) and presented as a standardised mean difference (Hedges' g ES). Using a random effects model, meta-analyses computed a pooled ES with 95% confidence intervals (CI), p-values and the I^2 statistic. Statistical heterogeneity was considered important if I^2 exceeded 60%⁹, and explored using subgroups. The following comparisons were planned to assess the primary outcome:

1. Pooled effects of augmentation intervention/comparator categories (i.e. psychological treatment, psychological comparator, pharmacological treatment and pharmacological comparator).
2. Pooled effects of augmenters by class (e.g. SSRI, SNRI, antipsychotic, mood stabiliser).
3. Pooled effects of individual treatment interventions within above categories.

Additional comparisons

We planned to explore secondary outcomes quantitatively or qualitatively, comprising: Acceptability, tolerability, and an exploration of pairwise active-control comparisons to provide an indicated effect of treatment versus comparator trial arm, validating findings against the currently considered gold standard¹⁰.

Subgroups used to explore heterogeneity

Planned subgroups used to explore statistical heterogeneity included study quality (RoB) and trial duration, as well as participant treatment-resistance definition, continuation treatments, comorbidities, depression severity, duration of episode and treatment setting.

Changes made since protocol registration

The permitted range of treatment duration was amended from 6-26 weeks to include any duration where expectations of clinical efficacy were reported. This was to account for the variable windows of clinical efficacy between different treatment mechanisms (e.g. ketamine, which has well-documented rapid antidepressant effects). Excluding ketamine, the MTI recommends durations of 6 weeks for full clinical effect¹; therefore we selected to subgroup included trials of less than 6 weeks as “short-term” (this excludes rapid-onset treatments such as ketamine)¹ and those more than 26 weeks as “long-term” treatment durations.

--- Figure 1 about here ---

Results

Systematic search results

After duplicates were removed, 2246 manuscripts from the MEDLINE and ISI Web of Science databases (all years to 6th February 2018) and hand searches were screened. Of 297 full texts reviewed, 39 articles describing 28 studies were eligible for inclusion. A PRISMA flow chart presents a breakdown of the search process (Figure 1).

Characteristics of Included Studies

Within the 28 included RCTs, 5461 TRD participants were randomised. All analysed interventions were of parallel-group studies, with ten trials (36%) conducted in North America, seven (25%) in Europe, six (21%) in Asia, four (14%) across multiple continents and one (4%) in South America. The mean study size was 199 (SD=270, range 20–1293). The duration of interventions ranged from five days (ketamine¹¹) to 18 months (long-term psychoanalytic psychotherapy¹²), with a median duration of six weeks (IQR=2).

Characteristics of participants

Participants studied had a median age of 45 years (IQR=4), and 66% were female. All patients analysed had unremitted depression despite at least two adequate treatment trials in the current episode. Fifteen studies defined TRD fully retrospectively (using a minimum duration of previous treatments of 4 or 6 weeks) while twelve required at least one unsuccessful treatment retrospectively and one prospectively. One study undertook two treatment trials to determine treatment-resistance fully prospectively¹³. Most studies did not consider psychological treatments to contribute to TRD definition; only Fonagy et al. required one pharmacological and one psychological treatment failure as a minimum TRD criteria for study entry¹². Table 1 contains further details.

Quality assessment

Supplementary Table 1 contains the RoB ratings across criteria and studies. Twelve studies were rated as having a low RoB^{11,12,14–23}, twelve had a moderate RoB^{24–35}, and four had a high RoB^{13,36–38}. The most common individual criteria rated as a high RoB were being funded and/or conducted by an industrial sponsor (twelve trials) and not applying or reporting an intention-to-treat analysis (seven trials). Blinding was not always maintained but was often maximised where possible i.e. in the ketamine trial (reportedly double-blind¹¹), psychological trials (two out of three trials report blinding of outcome assessors^{12,18}) and open label studies (all but one³⁸ reporting blinded outcome raters).

--- Table 1 about here ---

Effectiveness of augmentation treatment

There was clinical diversity in the design (see Table 1), intervention and outcomes reported (see Supplementary Table 2) across studies.

Primary outcomes

Pre-post meta-analyses indicated improvements in depression with all interventions examined ($p < 0.001$). From 23 studies including 3246 patients, pharmacological treatments yielded an overall ES of 1.15 (95%CI 1.01-1.29, $I^2=82.7$). Psychological therapies as a category comprised 3 studies totalling 276 patients, showing similar effects (ES=1.43, 95%CI 0.50-2.36, $I^2=95.3$). For the majority of initial analyses conducted, severe heterogeneity limited the interpretability of comparisons (see Supplementary Table 3). The three studies with a high RoB contributed substantially to this heterogeneity, demonstrating either low³⁶ or high^{13,38} outlier effect sizes and the subgroup of active treatments trialled for a short-term duration (lithium²⁴, metyrapone¹⁴) showed an ES of 0.61 (95%CI 0.37-0.85, $I^2=0$); their removal from meta-analyses notably reduced heterogeneity. In contrast, long-term treatment trials of lithium¹⁵ and psychoanalytic psychotherapy¹² were homogeneous (ES=0.67, 95%CI 0.44-0.90, $I^2=4.6$) and did not affect heterogeneity of main analyses so were not excluded from analyses. Effects of all placebo trials (pill ES=0.78, psychological ES=0.94) exhibited findings similar to the sub-therapeutic duration pharmacological studies (ES=0.61) and consistently lower than active treatments; see Figure 2 and Table 2. All active treatment effects are displayed in Supplementary Figure 1 and control arms in Supplementary Figure 2.

--- Table 2 about here ---

Pharmacological treatment classes

Pharmacological interventions without high RoB trialled for a therapeutic duration had an effect size of 1.19 (95%CI 1.08-1.30; $I^2=64.6$).

N-methyl-D-aspartate (NMDA) targeting drugs showed the most consistent and large effect size of the pharmacological classes (ES=1.48, 95%CI 1.25-1.71, $I^2=0$), despite the individual agents included having different mechanisms of action.

Mood stabilisers demonstrated an overall effect size of 1.12 (95%CI 0.92-1.31, $I^2=23.6$), exhibiting low heterogeneity only. Lithium was the most frequently investigated mood stabiliser and had a slightly smaller ES than the overall class without heterogeneity (3 studies, ES=1.00, 95%CI 0.81-1.20, $I^2=0$).

Antipsychotics also had an effect size of 1.12 (95%CI 0.98-1.26, $I^2=75.0$), and exhibited heterogeneity likely due to differences between treatments within this class. Aripiprazole was the most frequently assessed antipsychotic and provided a consistent effect across four studies (ES=1.33, 95%CI 1.23-1.44, $I^2=0$).

Medications not falling into the above mechanisms were grouped together (trazodone, buspirone, thyroid hormone and dexmecamylamine), showing an ES of 1.36 (95%CI 1.09-1.63, $I^2=46.4$), comparable in terms of heterogeneity and effect size to the other pharmacological treatments.

Psychological treatment classes

The overall effect size of psychological therapies (3 studies; ES=1.43, 95%CI 0.50-2.36) contained substantial heterogeneity ($I^2=95.3$), likely due to different therapeutic modalities that we were not able to subgroup further due to lack of studies. Within this analysis, cognitive-behavioural therapy (CBT) had the highest effect size of all individual treatments (one study²⁵; ES=1.74) while psychoanalytic psychotherapy had the smallest (one study¹²; ES=0.59).

Publication bias was not apparent (detail available on request).

--- Figure 2 about here ---

Secondary outcomes

Active versus control (pairwise) meta-analyses

In order to validate the pre-post method against the currently considered gold standard, we conducted pairwise active/control comparisons. Due to data availability, only three treatment classes were examinable. Despite heterogeneity of therapies and studies, these proposed that psychological treatments were more beneficial than usual care or an active control (3 studies, ES=0.45, 95%CI 0.09-0.81, $I^2=63.8$). Antipsychotics showed effectiveness when compared to placebo (7 studies, ES=0.38, 95%CI 0.18-0.58, $I^2=59.4$). The number of mood stabiliser studies was lower in the pairwise comparison than in pre-post analyses due to a paucity of placebo-controlled trials, and were not significantly more effective than placebo (4 studies, ES=0.13, 95%CI -0.14 to 0.39, $p=0.34$, $I^2=0$).

Tolerability and acceptability

Tolerability and acceptability were defined differently between studies, and were not sufficiently homogeneous to consider quantitatively in meta-analyses.

Eight studies reported the total number of adverse events (AEs) occurring in each arm, higher in active versus placebo arms for most interventions but equally between active and placebo arms in the d-cycloserine¹⁶ and minocycline¹⁷ trials. This rate might be heavily influenced by a large number of AEs occurring in a minority of patients, and of 7 studies reporting the percentage of participants experiencing at least one adverse event, most were similar between treatment arms.

The highest dropout rate was in the ziprasidone intervention (41% in the lower dose arm)²⁶. There was a >10% discrepancy in participant dropout between arms in this study, as well as Heresco-Levy et al. (d-cycloserine 23% versus placebo 11%)¹⁶ and Husain et al. (minocycline 24% versus 10% placebo)¹⁷. No dropouts were reported in the CBT trial arms TAU and individual CBT (two patients withdrew from group CBT)²⁵ or from the 1-week lithium placebo-controlled study (either trial arm)²⁴.

Discussion

We included 28 studies, most containing low to moderate RoB, reporting effect estimates for the most prevalent TRD augmentation treatment strategies, using the definition of TRD most often used in clinical practice.

Meta-analytic estimates of treatment effects for resistant and non-resistant depression

In contrast to TRD, progress is evolving regarding the comparative effectiveness of common treatments for MDD, exemplified by a recent, extensive network meta-analysis³⁹: Cipriani et al. (2018) identified over 500 double-blind randomised trials of antidepressant monotherapy for MDD, in contrast with 28 we found for TRD augmentation, finding all to be significantly more effective than placebo. Another meta-analysis of pharmacological augmentation treatments for depression non-responsive to ≥ 1 antidepressant reported comparable effect sizes³. We anticipate smaller effect sizes within TRD populations. The greatest pre-post effect of augmentation that we report is for medications targeting the NMDA receptor, comprising of ketamine (antagonist), d-cycloserine (partial agonist) and minocycline (antagonist). This finding supports increasing attention towards drugs acting on this pathway, as illustrated by a network meta-analysis of pharmacological and somatic treatments for non-responsive depression reporting ketamine to have the strongest short-term efficacy of treatments studied⁴⁰. It is notable however, that this finding was based on three studies only; population or design differences between studies may have yielded stronger effects in these trials than if directly compared with other interventions. Ketamine produced the highest effect size of the NMDA medications and is particularly challenging to maintain interviewer blinding, although Su et al. reported the trial as double blind¹¹. Based on a larger number of studies, our findings also indicate that for patients with a history of two unsuccessful treatments in the current episode, aripiprazole is effective, but it is important to note that all trials investigating aripiprazole had a potential allegiance effect. The evidence is less certain (often assessed in open label designs^{15,28,38}) but promising for lithium. The World Federation of Societies of Biological Psychiatry Task Force recommends lithium as the first-line augmentation option for TRD, and quetiapine or aripiprazole as alternatives⁴¹; however, we identified only one randomised

quetiapine trial in the current review (found to be non-inferior to lithium). As such, it is clear that much more work in this field is required.

Effects of interventions versus placebo in randomised studies for TRD

Even a pill placebo response is variable under some methodological conditions, suggesting that there is some small scope for improvement for patients with TRD without augmenting with a new active treatment. The effect size and confidence intervals for placebo were heterogeneous across studies (as displayed in Supplementary Figure 2), demonstrating that indeed there are limitations to inferring the relative effects of interventions across diverse investigations. Placebo and active treatment outcomes will have been influenced by a multitude of factors which differed across trials (including but not limited to the maintenance of blinding, analyses undertaken, inclusion criteria relating to comorbidities, severity, etc.). Notwithstanding, it does appear that as a whole both psychological and pharmacological treatments are more effective than either pill or psychological controls, even for already resistant patients. Specifically, the treatment classes whose pre-post confidence interval did not overlap with the pill placebo estimates were mood stabilisers, antipsychotics, NMDA drugs and medications with 'other' mechanisms. This was not the case for psychological treatments which contained a wide confidence interval, or for short-term treatment durations.

Effectiveness of psychological versus pharmacological intervention

For MDD, psychological therapies demonstrate overall comparable effect sizes to pharmacological interventions, according to a meta-analysis of direct comparisons⁴². The most recent review investigating psychological treatments for TRD identified only two randomised studies, both underpowered and defining TRD loosely; one had found comparable benefits of CBT and antidepressants, while the other reported clinical benefits of CBT but not antidepressants⁴³. The importance of building the psychological evidence base is clear and we predict that over the next decade growing efforts in this field will reduce current uncertainty of their effectiveness for this patient population⁴⁴.

Many psychological trials were excluded from the current review, as they focused on chronicity or recurrence of depression rather than the number of failed treatments. This limitation reflects the lack of integration between psychological and pharmacological fields and the difficulty in operationalising a measure of treatment response particularly for past psychological therapies (including treatment adequacy, adherence, dose, duration, intensity and other factors likely to influence outcome). The COBALT RCT has been seminal in the field, finding CBT adjunct to usual care as clinically effective (odds ratio of 3.26)⁴⁵, but was not eligible for inclusion in the current review due to only requiring non-response to 6 weeks of one ongoing antidepressant. It is important to note that for most patients with TRD, a combination of pharmacological and psychological approaches may be the most effective treatment both in terms of acute response and relapse prevention⁴⁶ although only pharmacological continuation treatments were focused on in the original studies included in this review.

Limitations and Strengths

This work highlights the weakness of the evidence base for augmentation treatments for TRD. Inconsistency of TRD definition excluded a large number of studies, and mediating and moderating factors (such as TRD or baseline severity, continuation treatments and case-mix of included patients) limited the ability to control confounders. However, 5034 participants from 23 studies exhibited consistency of findings. Limited comparable data were available on the tolerability and acceptability alongside effectiveness and we were not able to consider the influence of patient/investigator blinding, ITT analyses or allegiance effects in meta-analyses. These factors may have influenced effect sizes, although have not notably affected similar results in other reviews^{4,39}. Due to the limited number of psychological studies included, uncertainty remains over the benefit of CBT, psychoanalytic therapy and mindfulness-based cognitive therapy in this population.

Meta-analytic comparisons between treatment types have been deemed unsuitable (unless compared directly in original studies), but pre-post meta-analysis provides indications of effectiveness that can be compared between modalities. The pre-post analysis approach may show larger effect sizes due to spontaneous or natural remission, or patient expectations of effectiveness¹⁰ but the likelihood of this is attenuated in TRD populations who have experienced non-effective treatments and have a lower natural recovery rate than MDD as a whole. These also

therefore reflect effects as seen in real-world clinical practice. Pre-post analysis has the advantage of permitting comparisons between different treatment types and controls, which traditional meta-analysis is not suitable for (e.g. drug placebo pills have a larger effect than a waiting list control⁴, although no waiting list controls were examined in the present studies). In spite of these advantages it must be highlighted that indirectly comparing effect sizes between treatments in this way does not account for between-study variability (including but not limited to sociodemographic and clinical differences between patients recruited, the adequacy and delivery of treatment, and other procedural and analytic distinctions).

Clinical Implications

There has been continued controversy surrounding the comparison of psychological and medication-based treatment for depression. We have not found strong evidence that either one or the other is more effective in TRD specifically, although we highlight an urgent need for more intensive investigation of psychological therapy programs. This study also illustrates that a short duration of treatment affects outcomes more than differences between treatment modalities. However, our results indicate that both psychological and pharmacological treatments are more effective than either pill or psychological control, even for already resistant patients. Far from being ‘lost causes’, our findings demonstrate that more therapeutic work is needed to achieve an optimal response for this subpopulation of patients. Specifically, clinicians should not rule out CBT if it is being delivered with sufficient intensity and skilled therapists²⁵. Our findings also support previous work indicating that aripiprazole and, to a lesser extent, lithium are effective treatments, supporting their current recommendation as first-line therapies³¹. Although the measured effect sizes with these two pharmacotherapies are similar to other options, the fact that they have been more thoroughly investigated in a larger number of studies underlines their status as first-choice options. Although unconfirmed, even if some medication-based treatments are shown to possess greater efficacy overall in TRD, treatment decisions should necessarily remain a clinical judgement, in which clinicians need to balance difficulties with tolerability of medications in addition to the durability of effects and, vitally, patient preference when deciding on the most appropriate treatments to use. We continue to advocate pre-post meta-analyses and network meta-analyses following future primary RCTs to provide further assistance to clinicians for predicting the optimal treatment modality/ies for patients with TRD.

Summary

Despite advances in the treatment of affective disorders, both clinical response to and tolerance of current pharmacological agents is often poor^{2,47}. This is particularly so for patients with TRD, for whom there is a wide range of treatment options that may be suitable, but very little consensus on which are the most effective and tolerable⁴⁶. Our analyses provide both absolute (pre-post) and relative (pairwise) effect estimates for augmentation treatment strategies investigated for treatment-resistant depression, using the definition of TRD most often used in clinical practice. Based on our results, ketamine and other NMDA-targeting drugs, as well as buspirone and trazodone, hold particular promise for the future of evidence-based TRD treatments.

References

1. Fekadu A, Donocik JG, Cleare AJ. Standardisation framework for the Maudsley staging method for treatment resistance in depression. *BMC Psychiatry*. 2018 Apr 11;18:100.
2. Fekadu A, Wooderson SC, Markopoulou K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. *J Affect Disord*. 2009;116(1):4–11.
3. Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, et al. Comparative Efficacy, Acceptability, and Tolerability of Augmentation Agents in Treatment-Resistant Depression: Systematic Review and Network Meta-Analysis. *J Clin Psychiatry*. 2015 Apr;76(4):E487+.
4. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. *Int Clin Psychopharmacol*. 2015 Jul;30(4):183–92.
5. Strawbridge R, Carter B, Marwood L, Taylor R, Mantingh T, Nikolova V, et al. Efficacy of psychological and pharmacological augmentation therapies for treatment-resistant depression: a systematic review and meta-analysis [Internet]. PROSPERO: The

International Prospective Register of Systematic Reviews; 2018. Available from:

http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018088009

6. Conway CR, George MS, Sackeim HA. Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression: When Enough Is Enough. *JAMA Psychiatry*. 2017 Jan 1;74(1):9–10.
7. NICE. Depression in adults: treatment and management. National Institute for Health and Care Excellence (UK); 2017.
8. Scottish Intercollegiate Guidelines Network (SIGN). Methodology checklist 2: controlled trials [Internet]. 2012. Available from: <http://www.sign.ac.uk>
9. Higgins J, Green S (Editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. [Internet]. The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org
10. Cuijpers P, Weitz E, Cristea IA, Twisk J. Pre-post effect sizes should be avoided in meta-analyses. *Epidemiol Psychiatr Sci*. 2017 Aug;26(4):364–8.
11. Su T-P, Chen M-H, Li C-T, Lin W-C, Hong C-J, Gueorguieva R, et al. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. *Neuropsychopharm*. 2017 Dec;42(13):2482–92.
12. Fonagy P, Rost F, Carlyle J-A, Mcpherson S, Thomas R, Fearon RMP, et al. Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS). *World Psychiatry*. 2015 Oct;14(3):312–21.
13. Yoshimura R, Kishi T, Hori H, Ikenouchi-Sugita A, Katsuki A, Umene-Nakano W, et al. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012 Dec 3;39(2):355–7.
14. McAllister-Williams RH, Anderson IM, Finkelmeyer A, Gallagher P, Grunze HCR, Haddad PM, et al. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. *Lancet Psychiatry*. 2016 Feb;3(2):117–27.
15. Girlanda F, Cipriani A, Agrimi E, Appino MG, Barichello A, Beneduce R, et al. Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: results and lessons of an underpowered randomised clinical trial. *BMC Res Notes*. 2014 Oct 17;7:731.
16. Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. *Int J Neuropsychopharmacol*. 2013 Apr;16(3):501–6.
17. Husain M I, Chaudhry IB, Husain N, Khoso AB, Rahman RR, Hamirani MM, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial. *J Psychopharmacol (Oxf)*. 2017 Sep;31(9):1166–75.
18. Eisendrath SJ, Gillung E, Delucchi KL, Segal ZV, Nelson JC, McInnes LA, et al. A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression. *Psychother Psychosom*. 2016;85(2):99–110.
19. Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. *J Clin Psychopharmacol*. 2011 Oct;31(5):638–42.
20. Nierenberg A, Papakostas G, Petersen T, Montoya H, Worthington J, Tedlow J, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. *J Clin Psychopharmacol*. 2003 Feb;23(1):92–5.
21. Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. *Prim Care Companion J Clin Psychiatry*. 2008;10(3):187–90.
22. Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants. *J Clin Psychiatry*. 2015 Sep;76(9):1224+.
23. Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, et al. Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study. *J Clin Psychiatry*. 2015 Sep;76(9):1232+.
24. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. *J Clin Psychopharmacol*. 1996 Aug;16(4):307–14.
25. Hauksson P, Ingibergsdottir S, Gunnarsdottir T, Jonsdottir IH. Effectiveness of cognitive behaviour therapy for treatment-resistant depression with psychiatric comorbidity: comparison of individual versus group CBT in an interdisciplinary rehabilitation setting. *Nord J Psychiatry*. 2017;71(6):465–72.
26. Dunner DL. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study (July, pg 1071, 2007). *J Clin Psychiatry*. 2007 Sep;68(9):1448.
27. Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. *J Clin Psychiatry*. 2011 Oct;72(10):1405–12.
28. Bauer M, Dell’Osso L, Kasper S, Pitchot W, Vansvik ED, Koehler J, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. *J Affect Disord*. 2013 Oct;151(1):209–19.
29. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2007 Jun;68(6):843–53.
30. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants. *CNS Spectr*. 2009 Apr;14(4):197–206.
31. Maes M, Vandoelaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. *J Affect Disord*. 1996 Dec 16;41(3):201–10.

32. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder - A second multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychopharmacol*. 2008 Apr;28(2):156–65.
33. Moller H-J, Demyttenaere K, Olausson B, Szamosi J, Wilson E, Hosford D, et al. Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. *World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry*. 2015 Oct;16(7):483–501.
34. Ozaki N, Otsubo T, Kato M, Higuchi T, Ono H, Kamijima K. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. *Psychiatry Clin Neurosci*. 2015 Jan;69(1):34–42.
35. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. *Am J Psychiatry*. 2001 Jan;158(1):131–4.
36. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. *Am J Psychiatry*. 2006 Sep;163(9):1519–1530; quiz 1665.
37. Patkar AA, Masand PS, Pae C-U, Peindl K, Hooper-Wood C, Mannelli P, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. *J Clin Psychopharmacol*. 2006 Dec;26(6):653–6.
38. Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. *Int Clin Psychopharmacol*. 2007 May;22(3):179–82.
39. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet*. 2018 Apr 7;391(10128):1357–66.
40. Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. *Curr Med Res Opin*. 2017 Apr;33(4):701–11.
41. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry*. 2013 Jul 1;14(5):334–85.
42. Amick HR, Gartlehner G, Gaynes BN, Forneris C, Asher GN, Morgan LC, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. *BMJ*. 2015 Dec 8;351:h6019.
43. McPherson S, Cairns P, Carlyle J, Shapiro DA, Richardson P, Taylor D. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. *Acta Psychiatr Scand*. 2005 May 1;111(5):331–40.
44. Holmes EA, Ghaderi A, Harmer CJ, Ramchandani PG, Cuijpers P, Morrison AP, et al. The Lancet Psychiatry Commission on psychological treatments research in tomorrow's science. *Lancet Psychiatry*. 2018 Mar 1;5(3):237–86.
45. Wiles N, Thomas L, Abel A, Ridgway N, Turner N, Campbell J, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBaT randomised controlled trial. *Lancet*. 2013 Feb 2;381(9864):375–84.
46. Cleare A, Pariente CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. *J Psychopharmacol Oxf Engl*. 2015 May;29(5):459–525.
47. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. *Curr Psychiatry Rep*. 2007 Dec;9(6):449–59.

Acknowledgements

This study represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust (SLaM) and King's College London (KCL). The NIHR BRC had no involvement in study design, data collection, analysis or the decision to submit for publication. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Full details of authors

Rebecca Strawbridge BSc MSc PhD. Post-doctoral Research Associate. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, PO74 103 Denmark Hill, London, SE5 8AZ, UK.

Ben Carter BSc MSc PhD. Senior Lecturer in Biostatistics. Department of Biostatistics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.

Lindsey Marwood BSc MSc PhD. Post-doctoral Trial Manager. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, PO74 103 Denmark Hill, London, SE5 8AZ, UK.

Borwin Bandelow MD, PhD. Professor of Psychiatry and Neurology. Department of Psychiatry and Psychotherapy, University Medical Centre, Göttingen, Germany.

Dimosthenis Tsapekos BSc MSc. PhD student. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, PO74 103 Denmark Hill, London, SE5 8AZ, UK.

Viktoriya Nikolova BSc MRes. Research Assistant. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, PO72 De Crespigny Park, London, SE5 8AF, UK.

Rachael Taylor BA MSc. PhD student. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, PO74 103 Denmark Hill, London, SE5 8AZ, UK.

Tim Mantingh BSc MSc. Research Assistant. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, PO74 103 Denmark Hill, London, SE5 8AZ, UK.

Valeria de Angel BSc MSc. Research Assistant. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, PO74 103 Denmark Hill, London, SE5 8AZ, UK.

Fiona Patrick BSc MSc. PhD student. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, PO74 103 Denmark Hill, London, SE5 8AZ, UK.

Anthony J Cleare BSc MBBS PhD FRCPsych. Professor of Psychopharmacology. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, PO74 103 Denmark Hill, London, SE5 8AZ, UK.

Allan H Young MBChB MPhil PhD FRCPsych FRCPC FRSB. Professor of Mood Disorders. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, PO72 De Crespigny Park, London, SE5 8AF, UK.

Author contributions

All authors approved the publication of the manuscript. The additional contributions by individual authors are summarised below.

RS contributed to study design and methodology, data collection and analysis, interpretation of findings, drafting and revising the manuscript.

BC contributed to data analysis methodology, study inclusion, data extraction and analysis, interpretation and critical revision of the article.

LM contributed to study design, study inclusion and data collection, and critical revision of the manuscript.

BB contributed to the study conception and design, presentation of results and critical revision of the manuscript.

DT contributed to data collection and interpretation, drafting and revisions of the manuscript.

VN, RT, TM, VA and VP contributed to data collection and interpretation and manuscript revisions.

AJC contributed to study design, study inclusion and critical revisions of the manuscript.

AHY was responsible for study conception and supervised design, study inclusion and data interpretation as well as article drafting and revisions.